AIS Biotech relies on innovative, efficient, industrializable biotechnology with low environmental impact, to develop a new class of anti-infective biomedicines. Click on the title for more information.
The technology licensed to AIS Biotech is based on the historical work of Cermav, which was matured in collaboration with the CIRI laboratory in Lyon thanks to funding from SATT Linksium.
It is highlighted in CNRS Innovation Letter.
A lire aussi
Moustoifa Said thesis defense on March 21th, 2023
20 March 2023
par directioncermav
Structural Glycoscience Summer School 2023 in Grenoble (from June 5th to 7th, 2023)
10 March 2023
par directioncermav
PhD position "Custom chemical glycosylation of recombinant proteins"
10 March 2023
par directioncermav